Peroxisome proliferator-activated receptor-gamma agonists suppress tissue factor overexpression in rat balloon injury model with paclitaxel infusion

Jun Bean Park, Baek Kyung Kim, Yoo Wook Kwon, Dominik N. Muller, Hyun Chae Lee, Seock Won Youn, Young Eun Choi, Sae Won Lee, Han Mo Yang, Hyun Jai Cho, Kyung Woo Park, Hyo Soo Kim

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The role and underlying mechanisms of rosiglitazone, a peroxisome proliferator-activated receptor-gamma (PPAR-γ) agonist, on myocardial infarction are poorly understood. We investigated the effects of this PPAR-γ agonist on the expression of tissue factor (TF), a primary molecule for thrombosis, and elucidated its underlying mechanisms. The PPAR-γ agonist inhibited TF expression in response to TNF-α in human umbilical vein endothelial cells, human monocytic leukemia cell line, and human umbilical arterial smooth muscle cells. The overexpression of TF was mediated by increased phosphorylation of mitogen-activated protein kinase (MAPK), which was blocked by the PPAR-γ agonist. The effective MAPK differed depending on each cell type. Luciferase and ChIP assays showed that transcription factor, activator protein-1 (AP-1), was a pivotal target of the PPAR-γ agonist to lower TF transcription. Intriguingly, two main drugs for drug-eluting stent, paclitaxel or rapamycin, significantly exaggerated thrombin-induced TF expression, which was also effectively blocked by the PPAR-γ agonist in all cell types. This PPAR-γ agonist did not impair TF pathway inhibitor (TFPI) in three cell types. In rat balloon injury model (Sprague-Dawley rats, n = 10/group) with continuous paclitaxel infusion, the PPAR-γ agonist attenuated TF expression by 70±5% (n = 4; P<0.0001) in injured vasculature. Taken together, rosiglitazone reduced TF expression in three critical cell types involved in vascular thrombus formation via MAPK and AP-1 inhibitions. Also, this PPAR-γ agonist reversed the paclitaxel-induced aggravation of TF expression, which suggests a possibility that the benefits might outweigh its risks in a group of patients with paclitaxel-eluting stent implanted.

Original languageEnglish (US)
Article numbere28327
JournalPloS one
Volume6
Issue number11
DOIs
StatePublished - Nov 29 2011

Fingerprint

paclitaxel
PPAR gamma
Balloons
Thromboplastin
Paclitaxel
agonists
Rats
rats
Wounds and Injuries
rosiglitazone
Mitogen-Activated Protein Kinases
mitogen-activated protein kinase
Stents
Transcription Factor AP-1
Thrombosis
transcription factors
Cells
cells
umbilicus
Umbilicus

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)
  • General

Cite this

Peroxisome proliferator-activated receptor-gamma agonists suppress tissue factor overexpression in rat balloon injury model with paclitaxel infusion. / Park, Jun Bean; Kim, Baek Kyung; Kwon, Yoo Wook; Muller, Dominik N.; Lee, Hyun Chae; Youn, Seock Won; Choi, Young Eun; Lee, Sae Won; Yang, Han Mo; Cho, Hyun Jai; Park, Kyung Woo; Kim, Hyo Soo.

In: PloS one, Vol. 6, No. 11, e28327, 29.11.2011.

Research output: Contribution to journalArticle

Park, JB, Kim, BK, Kwon, YW, Muller, DN, Lee, HC, Youn, SW, Choi, YE, Lee, SW, Yang, HM, Cho, HJ, Park, KW & Kim, HS 2011, 'Peroxisome proliferator-activated receptor-gamma agonists suppress tissue factor overexpression in rat balloon injury model with paclitaxel infusion', PloS one, vol. 6, no. 11, e28327. https://doi.org/10.1371/journal.pone.0028327
Park, Jun Bean ; Kim, Baek Kyung ; Kwon, Yoo Wook ; Muller, Dominik N. ; Lee, Hyun Chae ; Youn, Seock Won ; Choi, Young Eun ; Lee, Sae Won ; Yang, Han Mo ; Cho, Hyun Jai ; Park, Kyung Woo ; Kim, Hyo Soo. / Peroxisome proliferator-activated receptor-gamma agonists suppress tissue factor overexpression in rat balloon injury model with paclitaxel infusion. In: PloS one. 2011 ; Vol. 6, No. 11.
@article{e0c3949205e6425b9550ebcb0da33195,
title = "Peroxisome proliferator-activated receptor-gamma agonists suppress tissue factor overexpression in rat balloon injury model with paclitaxel infusion",
abstract = "The role and underlying mechanisms of rosiglitazone, a peroxisome proliferator-activated receptor-gamma (PPAR-γ) agonist, on myocardial infarction are poorly understood. We investigated the effects of this PPAR-γ agonist on the expression of tissue factor (TF), a primary molecule for thrombosis, and elucidated its underlying mechanisms. The PPAR-γ agonist inhibited TF expression in response to TNF-α in human umbilical vein endothelial cells, human monocytic leukemia cell line, and human umbilical arterial smooth muscle cells. The overexpression of TF was mediated by increased phosphorylation of mitogen-activated protein kinase (MAPK), which was blocked by the PPAR-γ agonist. The effective MAPK differed depending on each cell type. Luciferase and ChIP assays showed that transcription factor, activator protein-1 (AP-1), was a pivotal target of the PPAR-γ agonist to lower TF transcription. Intriguingly, two main drugs for drug-eluting stent, paclitaxel or rapamycin, significantly exaggerated thrombin-induced TF expression, which was also effectively blocked by the PPAR-γ agonist in all cell types. This PPAR-γ agonist did not impair TF pathway inhibitor (TFPI) in three cell types. In rat balloon injury model (Sprague-Dawley rats, n = 10/group) with continuous paclitaxel infusion, the PPAR-γ agonist attenuated TF expression by 70±5{\%} (n = 4; P<0.0001) in injured vasculature. Taken together, rosiglitazone reduced TF expression in three critical cell types involved in vascular thrombus formation via MAPK and AP-1 inhibitions. Also, this PPAR-γ agonist reversed the paclitaxel-induced aggravation of TF expression, which suggests a possibility that the benefits might outweigh its risks in a group of patients with paclitaxel-eluting stent implanted.",
author = "Park, {Jun Bean} and Kim, {Baek Kyung} and Kwon, {Yoo Wook} and Muller, {Dominik N.} and Lee, {Hyun Chae} and Youn, {Seock Won} and Choi, {Young Eun} and Lee, {Sae Won} and Yang, {Han Mo} and Cho, {Hyun Jai} and Park, {Kyung Woo} and Kim, {Hyo Soo}",
year = "2011",
month = "11",
day = "29",
doi = "10.1371/journal.pone.0028327",
language = "English (US)",
volume = "6",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "11",

}

TY - JOUR

T1 - Peroxisome proliferator-activated receptor-gamma agonists suppress tissue factor overexpression in rat balloon injury model with paclitaxel infusion

AU - Park, Jun Bean

AU - Kim, Baek Kyung

AU - Kwon, Yoo Wook

AU - Muller, Dominik N.

AU - Lee, Hyun Chae

AU - Youn, Seock Won

AU - Choi, Young Eun

AU - Lee, Sae Won

AU - Yang, Han Mo

AU - Cho, Hyun Jai

AU - Park, Kyung Woo

AU - Kim, Hyo Soo

PY - 2011/11/29

Y1 - 2011/11/29

N2 - The role and underlying mechanisms of rosiglitazone, a peroxisome proliferator-activated receptor-gamma (PPAR-γ) agonist, on myocardial infarction are poorly understood. We investigated the effects of this PPAR-γ agonist on the expression of tissue factor (TF), a primary molecule for thrombosis, and elucidated its underlying mechanisms. The PPAR-γ agonist inhibited TF expression in response to TNF-α in human umbilical vein endothelial cells, human monocytic leukemia cell line, and human umbilical arterial smooth muscle cells. The overexpression of TF was mediated by increased phosphorylation of mitogen-activated protein kinase (MAPK), which was blocked by the PPAR-γ agonist. The effective MAPK differed depending on each cell type. Luciferase and ChIP assays showed that transcription factor, activator protein-1 (AP-1), was a pivotal target of the PPAR-γ agonist to lower TF transcription. Intriguingly, two main drugs for drug-eluting stent, paclitaxel or rapamycin, significantly exaggerated thrombin-induced TF expression, which was also effectively blocked by the PPAR-γ agonist in all cell types. This PPAR-γ agonist did not impair TF pathway inhibitor (TFPI) in three cell types. In rat balloon injury model (Sprague-Dawley rats, n = 10/group) with continuous paclitaxel infusion, the PPAR-γ agonist attenuated TF expression by 70±5% (n = 4; P<0.0001) in injured vasculature. Taken together, rosiglitazone reduced TF expression in three critical cell types involved in vascular thrombus formation via MAPK and AP-1 inhibitions. Also, this PPAR-γ agonist reversed the paclitaxel-induced aggravation of TF expression, which suggests a possibility that the benefits might outweigh its risks in a group of patients with paclitaxel-eluting stent implanted.

AB - The role and underlying mechanisms of rosiglitazone, a peroxisome proliferator-activated receptor-gamma (PPAR-γ) agonist, on myocardial infarction are poorly understood. We investigated the effects of this PPAR-γ agonist on the expression of tissue factor (TF), a primary molecule for thrombosis, and elucidated its underlying mechanisms. The PPAR-γ agonist inhibited TF expression in response to TNF-α in human umbilical vein endothelial cells, human monocytic leukemia cell line, and human umbilical arterial smooth muscle cells. The overexpression of TF was mediated by increased phosphorylation of mitogen-activated protein kinase (MAPK), which was blocked by the PPAR-γ agonist. The effective MAPK differed depending on each cell type. Luciferase and ChIP assays showed that transcription factor, activator protein-1 (AP-1), was a pivotal target of the PPAR-γ agonist to lower TF transcription. Intriguingly, two main drugs for drug-eluting stent, paclitaxel or rapamycin, significantly exaggerated thrombin-induced TF expression, which was also effectively blocked by the PPAR-γ agonist in all cell types. This PPAR-γ agonist did not impair TF pathway inhibitor (TFPI) in three cell types. In rat balloon injury model (Sprague-Dawley rats, n = 10/group) with continuous paclitaxel infusion, the PPAR-γ agonist attenuated TF expression by 70±5% (n = 4; P<0.0001) in injured vasculature. Taken together, rosiglitazone reduced TF expression in three critical cell types involved in vascular thrombus formation via MAPK and AP-1 inhibitions. Also, this PPAR-γ agonist reversed the paclitaxel-induced aggravation of TF expression, which suggests a possibility that the benefits might outweigh its risks in a group of patients with paclitaxel-eluting stent implanted.

UR - http://www.scopus.com/inward/record.url?scp=82255179593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82255179593&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0028327

DO - 10.1371/journal.pone.0028327

M3 - Article

C2 - 22140576

AN - SCOPUS:82255179593

VL - 6

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 11

M1 - e28327

ER -